I’m not especially optimistic with regard to finding a “cure” for MS however the continued research does appear to be shedding some light on not only the precipitating factors and our susceptibility but what is more interesting to me in this article is the mention of the individualized reaction to medications we presently use to treat MS. (note: ADME=absorption, distribution, metabolism and excretion)
Sad that they identified the human leukocyte antigen (HLA) connection to MS almost 40 years ago and this angle of research is only taking off in recent years but I guess better late than never.
“The Multiple Sclerosis Genetic Burden (MSGB) Score. The GWAS approach opens possibilities for individual genetic risk score computations. By the end of 2011, the number of genomic regions associated with MS susceptibility was more than 50. With additional GWAS currently being performed, and meta-analysis compiling an ever growing number of studies, the count of MS associated variants will most likely surpass 100 in 2013.
The second avenue by which biomarker research is likely to impact MS care is in the prediction of therapeutic response. This is an area of intense research and represents a shift in the previously widespread notion (particularly in the pharmaceutical industry) that all patients are equally likely to respond to a given drug. Recent data on the architecture of the human genome have unequivocally shown that there is abundant genetic variation between individuals that could account for differential ADME profiles, drug metabolism, transport, safety, and ultimately, response to pharmacological agents.”
http://onlinelibrary.wiley.com/doi/1...2.01134.x/full
Sad that they identified the human leukocyte antigen (HLA) connection to MS almost 40 years ago and this angle of research is only taking off in recent years but I guess better late than never.
“The Multiple Sclerosis Genetic Burden (MSGB) Score. The GWAS approach opens possibilities for individual genetic risk score computations. By the end of 2011, the number of genomic regions associated with MS susceptibility was more than 50. With additional GWAS currently being performed, and meta-analysis compiling an ever growing number of studies, the count of MS associated variants will most likely surpass 100 in 2013.
The second avenue by which biomarker research is likely to impact MS care is in the prediction of therapeutic response. This is an area of intense research and represents a shift in the previously widespread notion (particularly in the pharmaceutical industry) that all patients are equally likely to respond to a given drug. Recent data on the architecture of the human genome have unequivocally shown that there is abundant genetic variation between individuals that could account for differential ADME profiles, drug metabolism, transport, safety, and ultimately, response to pharmacological agents.”
http://onlinelibrary.wiley.com/doi/1...2.01134.x/full
Comment